Texas Children's Hospital -Research Resource Office
Welcome,         Profile    Billing    Logout  
 0 Trials 
6 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Huang, Clifton
ABX464-105, NCT05507203: ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1

Recruiting
3
612
Europe, Canada, US, RoW
ABX464, Obefazimod, Placebo
Abivax S.A.
Ulcerative Colitis
03/25
04/25
ABTECT, NCT05535946: - Maintenance

Recruiting
3
1050
Europe, Canada, Japan, US, RoW
ABX464, Obefazimod, Placebo
Abivax S.A.
Ulcerative Colitis
01/26
01/30
AMAY, NCT05509777 / 2022-000811-29: A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease

Recruiting
3
90
Europe, Canada, Japan, US, RoW
Mirikizumab, LY3074828
Eli Lilly and Company, Eli Lilly and Company
Crohn's Disease
07/27
10/27
SHINE-ON, NCT04844606 / 2020-005311-49: A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease

Recruiting
3
150
Europe, Japan, US, RoW
Mirikizumab, LY3074828
Eli Lilly and Company, Eli Lilly and Company
Ulcerative Colitis, Ulcerative Colitis Chronic, Inflammatory Bowel Diseases, Crohn's Disease
07/30
07/30
NCT06792838: Endomicroscopic Evaluation of Food-induced Gastrointestinal Mucosal Alteration

Not yet recruiting
N/A
200
NA
Confocal Laser Endomicroscopy
Cook Children's Health Care System, University of Nebraska Medical Center and Children's Hospital & Medical Center, Stanford University, Metrodora Institute, Meliora Bio ApS
Irritable Bowel Syndrome, Food Allergy
09/33
09/34
Karam, Lina Boujaoude
AMAY, NCT05509777 / 2022-000811-29: A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease

Recruiting
3
90
Europe, Canada, Japan, US, RoW
Mirikizumab, LY3074828
Eli Lilly and Company, Eli Lilly and Company
Crohn's Disease
07/27
10/27

Download Options